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Abstract 
The SARS-CoV-2 coronavirus, the etiologic agent responsible for COVID-19 coronavirus 
disease, is a global threat. To better understand viral tropism, we assessed the RNA 
expression of the coronavirus receptor, ACE2, as well as the viral S protein priming 
protease TMPRSS2 thought to govern viral entry in single-cell RNA-sequencing (scRNA-
seq) datasets from healthy individuals generated by the Human Cell Atlas consortium. 
We found that ACE2, as well as the protease TMPRSS2, are differentially expressed in 
respiratory and gut epithelial cells. In-depth analysis of epithelial cells in the respiratory 
tree reveals that nasal epithelial cells, specifically goblet/secretory cells and ciliated cells, 
display the highest ACE2 expression of all the epithelial cells analyzed. The skewed 
expression of viral receptors/entry-associated proteins towards the upper airway may be 
correlated with enhanced transmissivity. Finally, we showed that many of the top genes 
associated with ACE2 airway epithelial expression are innate immune-associated, 
antiviral genes, highly enriched in the nasal epithelial cells. This association with immune 
pathways might have clinical implications for the course of infection and viral pathology, 
and highlights the specific significance of nasal epithelia in viral infection. Our findings 
underscore the importance of the availability of the Human Cell Atlas as a reference 
dataset. In this instance, analysis of the compendium of data points to a particularly 
relevant role for nasal goblet and ciliated cells as early viral targets and potential 
reservoirs of SARS-CoV-2 infection. This, in turn, serves as a biological framework for 
dissecting viral transmission and developing clinical strategies for prevention and 
therapy. 
 
Introduction 
In December 2019, a cluster of atypical pneumonia associated with a novel coronavirus 
was detected in Wuhan, China1. This coronavirus disease, termed COVID-19, was caused 
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously termed 
2019-nCoV)2. The virus has since spread worldwide, emerging as a serious global health 
concern in early 20203,4. Human-to-human transmission of the virus has been reported in 
several instances5-7 and is thought to have occurred since mid-December 20198. As of 
early March 2020, there were more than 100,000 confirmed COVID-19 cases4.   
 
Patients with suspected COVID-19 have been treated in the Wuhan Jin Yintan Hospital 
since Dec 31st, 20199. In a meta-analysis of 50,466 hospitalized patients with COVID-19 
from 10 studies, most patients were from China and the average age in the included 
studies ranged from 41 to 56 years old10. The prevalence rates of fever, cough, and 
muscle soreness or fatigue were 89.1%, 72.2%, and 42.5%. Critical illness requiring 
admission to an intensive care unit occurred in 18.1% of patients, and 14.8% developed 
acute respiratory distress syndrome (ARDS)10. Acute renal injury and septic shock have 
been observed in 4% and 5% of patients hospitalized with COVID-19, respectively1,9. 
Chest imaging demonstrated bilateral pneumonia involvement in more than 80% of 
cases1,9,11. Ground-glass opacities were the most common radiologic finding on chest 
computed tomography (CT)11,12. Abnormalities on CT were also observed preceding 
symptom onset in patients exposed to infected individuals, with an incidence of 93%10,11. 
Pathological evaluation of a patient who died of severe disease revealed diffuse alveolar 
damage consistent with ARDS13. Currently, the estimated mortality rate is 3.4%14. These 
clinical data underscore the severity of this infection. The involvement of both lungs in 
most of the cases suggests viral dissemination after initial infection.  
 
Viral RNA was detected in the upper airways from symptomatic patients, with higher viral 
loads observed in nasal swabs compared to those obtained from the throat15. Similar 
viral loads were observed in an asymptomatic patient15, indicating that the nasal 
epithelium is an important portal for initial infection, and may serve as a key reservoir for 
viral spread across the respiratory mucosa and an important locus mediating viral 
transmission. Identification of the cells hosting viral entry and permitting viral replication 
as well as those contributing to inflammation and disease pathology is essential to 
improve diagnostic and therapeutic interventions.  
 
Cellular entry of coronaviruses depends on the binding of the spike (S) protein to a 
specific cellular receptor and subsequent S protein priming by cellular proteases. Similar 
to severe acute respiratory syndrome-associated coronavirus (SARS-CoV)16,17, the SARS-
CoV-2 employs angiotensin-converting enzyme-2 (ACE2) as a receptor for cellular entry. 
In addition, studies have shown that the serine protease TMPRSS2 can prime S 
protein15,18 although other proteases like cathepsin B/L can also be involved18. For SARS, 
the binding affinity between the S protein and the ACE2 receptor was found to be a 
major determinant of viral replication rates and disease severity19. The SARS-CoV-2 has 
been shown to infect and replicate in Vero cells, a Cercopithecus aethiops (old world 
monkey) kidney epithelial cell line, and huh7 cells, a human hepatocarcinoma cell line15. 
The BHK21 cell line has been shown to facilitate viral entry by the SARS-CoV-2 S protein 
only when engineered to express the ACE2 receptor ectopically18. In addition, viral entry 
was found to depend on TMPRSS2 activity, although cathepsin B/L activity might 
substitute for the loss of TMPRSS218. The in vivo expression of ACE2 and TMPRSS2 (as 
well as other candidate proteases) by cells of the upper and lower airways and alveoli 
must be defined. 
 
Previously, gene expression of ACE2 and TMPRSS2 has been reported to occur largely 
in type-2 alveolar (AT-2) epithelial cells15, which are central to SARS-CoV pathogenesis. 
A study reported that ACE2 expression is absent from the upper airways20. The rapid 
spread of the SARS-CoV-2 suggests efficient human-to-human transmission which 
would, in turn, seem to supersede the odds of dependency on alveolar epithelial cells 
as the primary point of entry and viral replication8,21,22. Indeed, protein expression, based 
on immunohistochemistry, of ACE2 and TMPRSS2 has been reported in both nasal and 
bronchial epithelium23. To clarify the expression patterns of ACE2 and TMPRSS2 and 
analyze the expression of the other potential genes associated with SARS-CoV-2 
pathogens at cellular resolution, we interrogated single-cell transcriptome expression 
data from published scRNA-seq datasets from healthy donors generated by the Human 
Cell Atlas consortium24.  
 
Results 
ACE2 and TMPRSS2 are enriched in nasal tissues and enterocytes  
We investigated the gene expression of ACE2 in multiple scRNA-seq datasets from 
different tissues, including those of the respiratory tree25, ileum26, colon27, liver28, 
placenta/decidua29, kidney30, testis31, pancreas32, and prostate gland33. While scRNA-seq 
is a comprehensive assay, we note that some studies may still miss specific cell types, 
due to either their rarity, challenges associated with their isolation, or analysis 
methodology that was used. Thus, while positive (presence) results are highly reliable, 
absence should be interpreted with care. 
 
The expression of ACE2, in general, is relatively low in all of the datasets analyzed. 
Consistent with independent analyses34, we found that ACE2 is expressed in lung, 
airways, ileum, colon, and kidney (Fig. 1a; first column). It is worth noting that TMPRSS2, 
the primary protease important for viral entry, is highly expressed with a broader 
distribution (Fig. 1a; second column), suggesting that ACE2, rather than TMPRSS2, may 
be a limiting factor for viral entry at the initial stage of infection. When taking into account 
the expression of both genes, the cells found in mucosal epithelia in the respiratory tree, 
ileum, and colon are ACE2+ (Fig. 1a; third column), consistent with viral transmission by 
respiratory droplets, and the potential of fecal-oral transmission35. We also assessed 
ACE2 and TMPRSS2 expression in developmental datasets from fetal liver, fetal thymus, 
fetal skin, fetal bone marrow and fetal yolk sac36,37 and found little to no expression of 
ACE2 with no co-expression with TMPRSS2 (data not shown) even if single ACE2 
expression is noticeable in certain cell types in placenta/decidua (Fig. 1a). While we 
cannot rule out the possibility that the virus uses alternative proteases for entry in such 
contexts, or that lung fetal tissue expresses the relevant genes, these results are at least 
consistent with early reports that fail to detect evidence of intrauterine infection through 
vertical transmission in women who develop COVID-19 pneumonia in late pregnancy38. 
If future epidemiologic data are consistent with a lack vertical viral transmission, these 
findings may form the basis of an explanatory model for the clinical finding. However, if 
future evidence for vertical transmission emerges, additional scRNA-seq data can be 
collected and further scrutinized for the presence of rare co-expressers or alternative 
receptors or proteases. 
 
Nasal goblet and ciliated cells display the highest expression of ACE2 within the larger 
population of respiratory epithelial cells 
To further characterize specific epithelial cell types expressing ACE2, we evaluated the 
expression of ACE2 within lung/airway epithelia from a previous study25. We found that, 
despite a low level of expression overall, ACE2 is expressed in multiple epithelial cell 
types across the airway, as well as in AT-2 cells in the parenchyma, consistent with 
previous studies20,39. Importantly, nasal epithelial cells, including previously described 
two clusters of goblet cells and one cluster of ciliated cells, have the highest expression 
among all investigated cells in the respiratory tree (Fig. 1b; left panel). We confirmed 
enriched ACE2 expression in nasal epithelial cells from a second scRNA-seq study, 
which, in addition to nasal brushing samples seen in the earlier dataset, included nasal 
biopsies40. The results were consistent: we found the highest expression of ACE2 in nasal 
secretory cells (equivalent to the two goblet cell clusters in the previous dataset) and 
ciliated cells (Fig. 1b; right panel).  
 
In addition, scRNA-seq data from an in vitro 3D epithelial regeneration system from nasal 
epithelial cells41 corroborated the expression of ACE2 in goblet/secretory cells and 
ciliated cells in these air-liquid interface (ALI) cultures (Extended Data Fig. 1). Of note, 
the differentiating cells in ALI acquire progressively more ACE2 and, unlike their 
corresponding progenitors, they have large luminal surfaces in the mature differentiated 
epithelium where viral entry is likely to occur (Extended Data Fig. 1). These results also 
suggest that such in vitro culture system is biologically relevant to the study of viral 
pathogenesis.  
 
We also investigated the expression of known proteases associated with the entry of 
SARS-CoV and SARS-CoV-2. TMPRSS2, which was shown to be important for SARS-
CoV/SARS-CoV-2 viral entry and SARS-CoV transmission,16-18 is expressed in a subset of 
ACE2+ cells (Extended Data Fig. 2), suggesting that the virus might use alternative 
pathways for entry. In fact, it was previously shown that SARS-CoV-2 could enter 
TMPRSS2- cells using cathepsin B/L18. Indeed, we found that they are much more 
promiscuously expressed than TMPRSS2, especially cathepsin B, which is expressed in 
more than 70%-90% of ACE2+ cells (Extended Data Fig. 2). However, whether cathepsin 
B/L can functionally replace TMPRSS2 has not been empirically determined. In the case 
of SARS-CoV, TMPRSS2 activity is documented to be important for viral transmission42,43. 
 
Respiratory expression of viral receptor/entry-associated genes and implications for 
viral transmissivity 
We next asked whether the enriched expression of viral receptors and entry-associated 
molecules in the nasal region/upper airway could be relevant to viral transmissivity. Here, 
we assessed the expression of viral receptor genes that are used by other coronaviruses 
and influenza viruses, including ANPEP (used by HCoV-22944) and DPP4 (used by MERS-
CoV45), as well as the enzymes ST6GAL1 and ST3GAL4 in the lung epithelial cell datasets. 
The latter genes are enzymes which are important for the synthesis of viral receptors 
used by influenza viruses: α(2,6)-linked sialic acid and α(2,3)-linked sialic acid46. Notably, 
the distribution of receptor/receptor-associated enzymes appears to coincide with viral 
transmissivity patterns based on a comparison to the basic reproduction number (R0), 
which estimates the number of people who can get infected from a single infected 
person; and the infection will be able to start spreading in a population when R0 > 1. The 
skewed distribution of the receptors/enzymes towards the upper airway is observed in 
viruses with relatively higher R0/infectivity, including those of SARS-CoV/SARS-CoV-2 (R0 
~ 1.4-5.08,21,22), influenza (mean R0 ~1.347) and HCoV-229E (unidentified R0; associated 
with common cold48). This distribution is in distinct contrast with that of DPP4, the 
receptor for MERS-CoV (R0 ~0.3-0.8), a coronavirus with limited human-to-human 
transmission49, with the skewed expression towards lower airway/lung parenchyma (Fig. 
2a). Therefore, our data highlight the possibility that viral transmissivity is dependent on 
receptor accessibility based on spatial distribution along the respiratory tract. 
  
Expression of genes associated with ACE2 expression: innate immunity and 
carbohydrate metabolism 
To gain more insight into the expression patterns of genes associated with ACE2, we 
performed Spearman correlation analysis with Benjamini-Hochberg-adjusted p-values on 
genes associated with ACE2 across all cells within the lung epithelial cell dataset25. While 
the correlation coefficients are relatively low (< 0.11), likely due to low expression of 
ACE2, the expression pattern of the top 50 ACE2-correlated genes (all with adjusted p-
value close to 0; ranked by correlation coefficients) across the respiratory tree is similar 
to that of ACE2, with a skewed expression toward upper airway (Fig. 2b). To our surprise, 
while some of the genes are associated with carbohydrate metabolism (possibly due to 
the role of goblet cells in mucin synthesis), a number of genes associated with immune 
functions including innate and antiviral immune functions,  are over-represented in the 
rank list, including IDO1, IRAK3, NOS2, TNFSF10, OAS1, and MX1 (Fig. 2b and 
Supplementary Table 1). These genes have the highest expression in nasal goblet 2 cells 
(Fig. 2b), consistent with the phenotype previously described25. Nonetheless, nasal 
goblet 1 and nasal ciliated 2 cells also significantly express these genes, but less so 
elsewhere (Fig. 2b). Given their environmental exposure and the high expression of 
receptor/receptor-associated enzymes (Fig. 2a), it is plausible that the nasal epithelial 
cells were conditioned and primed to express these immune-associated genes to 
prevent viral susceptibility. This association with innate immune pathways not only 
highlights the importance of host-microbe dynamics in nasal epithelia, but it may also 
have implications for subsequent viral pathogenesis and immune-associated 
protection/pathology. 
 
Discussion 
In this study, we explored multiple scRNA-seq datasets generated within the HCA 
consortium, and found that SARS-CoV-2 entry receptor ACE2 is more highly expressed 
(and co-expressed with viral entry-associated protease TMPRSS2) in nasal epithelial cells, 
specifically goblet and ciliated cells. This finding implicates these cells as loci of original 
infection and possible reservoirs for dissemination within a given patient and from person 
to person. Importantly, viral infection itself could drastically change the gene expression 
landscape in the nose and other tissues later on.  
 
The up-regulation of innate immune genes, in association with ACE2, in highly-exposed 
nasal epithelial cells could be the result of their responsiveness to persistent 
environmental challenges, including viral infection. It would be of great interest to further 
investigate how other genetic, demographic, and environmental factors might affect this 
poised state in these cells and whether such state could influence the susceptibility to 
infection due to its association with viral receptor expression. Future meta-analysis of 
HCA data can help further assess some of these aspects. 
 
All in all, our findings may have significant implications for understanding viral 
transmissivity, considering that the primary viral transmission is through respiratory 
droplets. Moreover, as SARS-CoV-2 is an enveloped virus, its release does not require 
cell lysis. Thus, the virus might exploit existing secretory pathways in nasal goblet cells 
for low-level, continuous-release at the early stage with no overt pathology. These 
discoveries could have clinical implications with respect to targeting nasal epithelial cells, 
especially nasal goblet cells, beyond the current usage of face masks, providing a 
candidate clinical option for transmission prevention and/or early-stage intervention.  
 
Finally, it is worth highlighting that this is the first collaborative effort by a Human Cell 
Atlas Biological Network (the Lung), and illustrates the opportunities from integrative 
analyses of Human Cell Atlas data, with future examples of consortium work expected 
soon.  
 
Methods 
The datasets were retrieved from existing sources based on previously published data 
as specifically specified in the reference. We retained the cell clustering when available 
or reprocessed using scanpy50 and harmony51, and annotated the clusters with marker 
genes and cell type nomenclature based on the respective studies. Illustration of the 
results was generated using scanpy50 and Seurat52.  
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Fig. 1| Expression of ACE2 and TMPRSS2 across different tissues and its enrichment in nasal 
epithelial cells. a, RNA expression of SARS-CoV-2 entry receptor ACE2 (first column), entry-associated 
protease TMPRSS2 (second column), and their co-expression (third column) from multiple published 
scRNA-seq datasets. Raw expression values were normalized, log transformed and summarized by 
published cell clustering where available, or reproduced clustering annotated using marker genes and cell 
type nomenclature from the respective studies. The size of the dots indicates the proportion of cells in the 
respective cell type having greater-than-zero expression of ACE2 (first column), TMPRSS2 (second column) 
or both (third column), while the colour indicates the mean expression of ACE2 (first and third columns) or 
TMPRSS2 (second column). b, Schematic illustration depicts the major anatomical regions in the human 
respiratory tree demonstrated in this study: nasal, lower airway, and lung parenchyma (left panel). 
Expression of ACE2 is from airway epithelial cell datasets: Vieira Braga, Kar et al. 2019 (middle panel) and 
Deprez et al. 2019 (right panel). The datasets were retrieved from existing sources, and the cell clustering 
and nomenclature were retained based on the respective studies. For gene expression results in the dot 
plots: the dot size represents the proportion of cells within the respective cell type expressing the gene 
and the dot color represents the average gene expression level within the particular cell type.
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Fig. 2| Respiratory expression of viral receptor/entry-associated genes and implications for viral 
transmissivity and genes associated with ACE2 expression. a, Expression of ACE2 (an entry receptor 
for SARS-CoV and SARS-CoV-2), ANPEP (an entry receptor for HCoV-229E), ST6GAL1/ST3GAL4 (enzymes 
important for synthesis of influenza entry receptors), and DPP4 (an entry receptor for MERS-CoV) from the 
airway epithelial datasets: Vieira Braga, Kar et al. 2019 (left panel) and Deprez et al. 2019 (right panel). The 
basic reproductive number (R0) for respective viruses, if available, are shown. b, Respiratory epithelial expression of the top 50 genes correlated with ACE2 expression based on Spearman correlation analysis 
(with Benjamini-Hochberg-adjusted p-values) on genes associated with ACE2 across all cells within the Vieira 
Braga, Kar et al. lung epithelial dataset. The colored gene names represent genes that are immune-associated 
(GO:0002376: immune system process or GO:0002526: acute inflammatory response). For gene expression 
results in the dot plots: the dot size represents the proportion of cells within the respective cell type expressing 
the gene and the color represents the average gene expression level within the particular cell type.
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Extended Data Figure 1
Extend Data Fig. 1| Gene expression of ACE2 in an in vitro 3D air-liquid interface (ALI) system. 
Epithelial regeneration system from nasal epithelial cells was used for in vitro cultures on successive 
days (7, 12 and 28), resulting in different epithelial cell types along differentiation trajectory characterized 
in Ruiz García et al. 2019. The cultures were differentiated in Pneumacult media. Schematic illustration 
depicts the respective cell types in the differentiation trajectory, and the dot plot illustrates the cultured 
cell types along the differentiation pseudotime, along with their respective location within the epithelial 
layers. For gene expression results in the dot plot: the dot size represents the proportion of cells within 
the respective cell type expressing the gene and the dot color represents the average gene expression 
level within the particular cell type. 
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Extended Data Fig. 2| Expression and co-expression of SARS-CoV-2 entry-associated proteases 
in ACE2+ airway epithelial cells: TMPRSS2, CTSB, and CTSL in ACE2+ cells from the Vieira Braga, Kar 
et al. (top) and Deprez et al. (bottom) airway epithelial datasets. The color represents the expression level 
at the single-cell resolution and the cells are grouped based on the cell types specified. 
  
 
Genes GO Accession Number: Class PathCards 
IDO1 GO:0002376: immune system process NF-kappaB Signaling Viral mRNA translation  
PI3 GO:0002376: immune system process Defensins, Innate Immune System 
CEACAM5 GO:0002376: immune system process NF-kappaB Signaling 
KYNU GO:0002376: immune system process Viral mRNA translation  
TCN1 GO:0002376: immune system process Innate Immune System NF-kappaB Signaling 
S100P GO:0002376: immune system process Innate Immune System 
IRAK3 GO:0002376: immune system process Innate Immune System 
TNFSF10 GO:0002376: immune system process TNF signaling 
NOS2 GO:0002376: immune system process Innate Immune System 
PTGES GO:0002526: acute inflammatory response  Prostaglandin 2 biosynthesis and metabolism FM 
MDK GO:0002376: immune system process NF-KappaB Family Pathway 
RAB37 GO:0002376: immune system process Innate Immune System 
ASS1 GO:0002376: immune system process Viral mRNA Translation 
OAS1 GO:0002376: immune system process Innate Immune System Immune response IFN alpha/beta signaling pathway 
MX1 GO:0002376: immune system process Innate Immune System Immune response IFN alpha/beta signaling pathway 
Supplementary Table 1| Immune-associated genes in respiratory epithelial expression from the top 50 
genes correlated with ACE2 expression based on Spearman correlation analysis (with Benjamini-
Hochberg-adjusted p-values) across all cells within the Vieira Braga, Kar et al. lung epithelial dataset. 
The characterization of genes was based on Gene Ontology classes from the Gene Ontology (GO) 
database and associated pathways in PathCards from the Pathway Unification Database.  
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